Actinium Pharmaceuticals Inc (ATNM) Implied Volatility Current

Tracking ATNM implied volatility helps you identify when options premiums on Actinium Pharmaceuticals Inc are historically cheap or expensive, and where the best trades are hiding. Actinium Pharmaceuticals Inc implied volatility reflects the market's expectation of future price movement: when ATNM IV rises, option premiums increase, creating opportunities for sellers, and when it drops, buyers can find cheaper contracts. Use our scanner to monitor Actinium Pharmaceuticals Inc's implied volatility current levels in real time and filter for high-probability trades.

Implied volatility is derived from option prices using models like Black-Scholes and represents the annualized expected move of an underlying stock. For ATNM, tracking metrics like ATNM IV rank helps traders understand whether current implied volatility is historically high or low. IV rank compares today's reading against the past year's range — a high rank on ATNM signals rich premiums and potential mean-reversion, while a low rank may favor long options strategies.

Actinium Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for bone marrow transplant (BMT) or a type of cellular therapy, and for other adoptive cell therapies. Its lead product candidate, I-131 apamistamab (Iomab-B) that is in a pivotal Phase III clinical trial for elderly relapsed or refractory acute myeloid leukemia trial for BMT conditioning; and a Phase I study with a CD19- targeted CAR T-cell therapy with memorial sloan kettering cancer center. The company also offers clinical and preclinical development programs that utilize multiple isotopes, including Actinium-225, Iodine-131, and Lutetium-177 directed at multiple validated cancer targets, including CD45, CD33, CD38, CD47, HER2, and HER3 for targeted conditioning prior to cell and gene therapies, such as bone marrow transplant and cancer therapeutics as single agents or in combination with other therapeutic modalities.

It has collaboration with Astellas Pharma, Inc. to develop theranostics for solid tumor indications; EpicentRx, Inc that focuses on a novel CD47 immunotherapy targeted radiotherapy; and AVEO Oncology that focuses on developing a HER3 targeting ARC for solid tumors. The company was incorporated in 2000 and is based in New York, New York.

Premium sellers, directional traders, and spread builders all need the same starting point: a clear read on where ATNM implied volatility sits today versus where it has been. Our scanner ranks Actinium Pharmaceuticals Inc implied volatility against its historical range, surfaces extremes in ATNM IV rank, and pairs every reading with the trades that exploit it. Stop guessing whether Actinium Pharmaceuticals Inc IV is rich or cheap — measure it, then act on it.